23:03 , Jul 18, 2019 |  BC Extra  |  Financial News

Medicxi’s new €400M fund unites early, late stage investing

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle. Medicxi III will deploy €400 million ($451.2 million) across...
21:14 , Jul 8, 2019 |  BC Extra  |  Financial News

Why Medicxi invested in Evotec’s DNA damage repair spinout

The opportunity to get into the DNA damage repair space was enough for Medicxi to bend its asset-centric rule and lead the €30 million ($33.7 million) series A round for Evotec spinout Breakpoint. Medicxi's Jon...